Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021

ResearchMoz.us includes new market research report “Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021” to its huge collection of research reports.

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets.

This has led to strong commercial interest in the development of T2DM therapeutics. The current market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic options available, the treatment algorithm is complex.

To Browse a Full Report with TOC: http://www.researchmoz.us/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-report.html

However, current treatment regimens are often associated with limited long-term efficacy, complex and inconvenient dosing regimens, and undesirable side effects such as weight gain and hypoglycemia (low blood glucose levels).

Reasons to buy:-

· Understand the clinical context of the T2DM indication and the global burden of the disease by considering epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, disease classification, disease prognosis, and treatment options

· Appreciate the current T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need

· Identify key pipeline trends in molecule type and molecular target

· Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections

· Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by phase of development, molecule type, and molecular target

· Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan

· Discover how strategic consolidations have shaped the current T2DM pipeline and marketed products landscapes

To Download Sample Report with TOC: http://www.researchmoz.us/enquiry.php?type=sample&repid=316445

Table of Contents:

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 9

2.1 Disease Overview 9

2.2 Epidemiology 9

2.3 Symptoms 10

2.4 Etiology 10

2.5 Pathophysiology 11

2.6 Co-morbidities and Complications 13

2.7 Classification 15

2.8 Prognosis 15

2.9 Diagnosis 16

2.10 Assessing Treatment Effectiveness 17

2.11 Treatment Algorithm 17

2.12 Non-insulin T2DM Therapies 19

2.12.1 Biguanides 19

To Read the Complete Report with Toc Visit: http://www.researchmoz.us/type-2-diabetes-mellitus-therapeutics-in-major-developed-markets-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-report.html

For More Information Kindly Contact:

ResearchMoz

Mr. Nachiket Ghumare, +1–518–621–2074

USA-Canada Toll Free: 866–997–4948

Email: sales@researchmoz.us

WebSite:http://www.researchmoz.us/